{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T20:37:46Z","timestamp":1781555866690,"version":"3.54.5"},"reference-count":14,"publisher":"Informa UK Limited","issue":"4","funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["HIV Research & Clinical Practice"],"published-print":{"date-parts":[[2020,7,3]]},"DOI":"10.1080\/25787489.2020.1824718","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T18:02:23Z","timestamp":1602612143000},"page":"105-113","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial"],"prefix":"10.1080","volume":"21","author":[{"given":"Miranda","family":"Murray","sequence":"first","affiliation":[{"name":"Health Analytics & Outcomes, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Kerrigan","sequence":"additional","affiliation":[{"name":"American University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krischan J.","family":"Hudson","sequence":"additional","affiliation":[{"name":"ViiV Healthcare, Research Triangle Park, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Walters","sequence":"additional","affiliation":[{"name":"GSK, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahilin Sanchez","family":"Karver","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mantsios","sequence":"additional","affiliation":[{"name":"American University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noya","family":"Galai","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01250.x"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000006"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200003303421303"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38398.590602.E0"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.844685"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_3_2_10_1","first-page":"21","volume-title":"10th IAS Conference","author":"Murray M","year":"2019","unstructured":"Murray M, et al. Patient-reported outcomes on long-acting cabotegravir\u2009+\u2009rilpivirine as maintenance therapy: FLAIR 48-week results. Poster presented at: 10th IAS Conference; July 21\u201324, 2019; Mexico City, Mexico, MOPEB258."},{"key":"e_1_3_2_11_1","first-page":"21","volume-title":"at: 10th IAS Conference","author":"Murray M","year":"2019","unstructured":"Murray M, et al. Patient views on long-acting HIV treatment: cabotegravir\u2009+\u2009rilpivirine as maintenance therapy (ATLAS 48-Week Results). Oral Presentation at: 10th IAS Conference; July 21\u201324, 2019; Mexico City, Mexico, MOAB0103."},{"key":"e_1_3_2_12_1","unstructured":"ATLAS-2M Press Release [cited August 31 2019]. Available from: https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/viiv-healthcare-reports-positive-phase-iii-study-results-of-investigational-long-acting-injectable-hiv-treatment-regimen-administered-every-two-months\/."},{"key":"e_1_3_2_13_1","first-page":"8","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Overton ET","year":"2020","unstructured":"Overton ET, Richmond GJ, Rizzardini G, et al. Cabotegravir\u2009+\u2009rilpivirine every 2 months is noninferior to monthly: ATLAS-2M study. Conference on Retroviruses and Opportunistic Infections (CROI); 2020:8\u201311; Boston, Abstract 34."},{"key":"e_1_3_2_14_1","unstructured":"Mantsios A Murray M Sanchez Karver T Davis W Margolis D. \"I feel empowered\": women's perspectives on and experiences with long-acting antiretroviral therapy in the United States and Spain. Infectious Disease Week (IDWeek). Washington DC; October 2 2019."},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190487"}],"container-title":["HIV Research & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/25787489.2020.1824718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T15:00:12Z","timestamp":1717599612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/25787489.2020.1824718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,3]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7,3]]}},"alternative-id":["10.1080\/25787489.2020.1824718"],"URL":"https:\/\/doi.org\/10.1080\/25787489.2020.1824718","relation":{},"ISSN":["2578-7489","2578-7470"],"issn-type":[{"value":"2578-7489","type":"print"},{"value":"2578-7470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhct21","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhct21","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}